NOP2 and neoplasm: Both in-frame fusions from advanced disease, ESR1-e6>YAP1 and ESR1-e6>PCDH11X, promoted estrogen-independent growth (Figure 2C, −E2), but the primary tumor fusion event, ESR1-e6>NOP2, had no growth-promoting properties.